Given recent data that specific inhibition of Caspase-1 inhibits NASH fibrosis (Dixon et al, 2013), it is possible that targeting of this respective pathway might also contribute to the beneficial effects of pan-caspase inhibitors in NASH fibrosis. This evidence concerns the gene CASP1 and metabolic dysfunction-associated steatohepatitis.